Viewing all links from the source for category: Pharma/Biotech

13/02/2026

Cochlear Limited Financial ResultsFor the half year ended December 2025

12/02/2026

Pro Medicus Limited interim results

Why eight Australians died after having AstraZeneca’s COVID vaccine

11/02/2026

AMPLIA THERAPEUTICS ANNOUNCES OPENING OF US SITES FOR AMPLICITY PANCREATIC CANCER TRIAL

Noxopharm: Sofra™ breakthrough science published in major medical journal

09/02/2026

Memphasys Secures TGA Approval for Felix(TM) System, Unlocking Commercial Sales in Australia – Memphasys Limited (ASX: MEM)

Mounjaro® (tirzepatide) now available in New Zealand for treatment of obesity and Type 2 diabetes – Eli Lilly New Zealand

06/02/2026

Neuren Pharmaceuticals: First patient dosed in Neuren’s Phelan-McDermid syndrome Phase 3 trial

05/02/2026

PYC Therapeutics: PYC RAISING UP TO $653M1 TO DELIVER HUMAN EFFICACY DATA FOR FOUR HIGH POTENTIAL DRUG CANDIDATES

PYC Therapeutics: COMPLETION OF PLACEMENT AND INSTITUTIONAL ENTITLEMENT OFFER

Neuren receives US FDA meeting feedback for NNZ-2591 clinical development in HIE and PTHS

Neuren Pharmaceuticals: Rare Pediatric Disease Priority Review Voucher program reauthorized by US Congress to September 2029

03/02/2026

ImmVirX and BeOne Medicines Enter Clinical Collaboration to Evaluate IVX055 in Combination with tislelizumab

Neuren Pharmaceuticals: Acadia provides update on regulatory submission for trofinetide for the treatment of Rett syndrome in the European Union

Proposed Little Green Pharma and Cannatrek Merger

AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need

02/02/2026

Emyria’s PTSD Program Delivers Lasting Recovery

LTR Pharma: SPONTAN® Nasal Spray Shows Positive Real-World Outcomes in Younger Men with Performance-Related Erectile Difficulties

Recce Enters Second U.S. Department of Defense R&D Agreement

PYC Therapeutics preps $600m-plus cash call, hires two banks

Mayne Pharma to return to court to fight Cosette for failed bid costs

30/01/2026

Optiscan: QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 DECEMBER 2025

Clarity: Quarterly Activities/Appendix 4C Cash Flow Report

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

Alterity Therapeutics: Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Paradigm Biopharma: December 2025 Quarterly Activities Report & Appendix 4C

Artrya: QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 DECEMBER 2025

Starpharma: Quarterly Activities Report & Appendix 4C

Emyria and Avive expand partnership into Victoria, bringing Empax clinic to the Mornington Peninsula; partnership accelerates Avive’s national assisted therapies program for mental health – Avive Health

29/01/2026

Paradigm Biopharma: Manuscript on Phase 2 iPPS Biomarker Study, PARA_OA_008, Accepted for Publication in Leading Peer-Reviewed Journal

Oncosil: TRIPP-FFX trial completes last patient, last visit

28/01/2026

EMYRIA ADVANCES NATIONAL EXPANSION VIA REIMBURSED EMPAX CLINIC NETWORK

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

LTR Pharma: Quarterly Activities Report & Appendix 4C For the Period Ending 31 December 2025

27/01/2026

Nexsen secures $500,000 Federal grant to expand rapid GBS diagnostics into neonatal care – Jane Morgan Management

Weight-loss ad blitz prompts warning from doctors

22/01/2026

Compumedics delivers record H1 FY26 sales orders; shipped revenue up 32%, positioning for stronger H2 and FY26 execution

Amplia: Narmafotinib Large-Scale Manufacture Complete

First Patients Dosed in SPONTAN® Phase II Clinical Study

OGTR: Clinical trial of genetically modified adenovirus for treatment of locally advanced rectal cancer

21/01/2026

Syntara: Amsulostat in pancreatic cancer Phase 1/2 clinical trial in collaboration with the Garvan, funded by MRFF

Noxopharm: HERACLES clinical trial successfully completed

AdCella milestones and regulatory progress

Neurizon Secures Global Trademark Protection Across Key Markets

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

lobal consultancy firm LEK Consulting backs ANDHealth to put real numbers behind Australia’s digital health impact

Burnet Partners with Atomo on Rapid Liver Test

20/01/2026

Telix: Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

19/01/2026

NRFC invests $20 million to help Omniscient Neurotechnology expand its revolutionary brain mapping technology around the world

16/01/2026

Advent stitches up $700m merger for Imaging Associates, taps UBS